A Phase 2 interventional study of Garadacimab and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by CSL Behring. Completed at 47 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 85th largest by enrollment of the 188 interventional ones that give a count, is one of 17 that started in 2022, is one of 82 in phase 2, and was the 168th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
Oorja Bio, Inc. · Sites in United States
Ages 40+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 17 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 85 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 1 study filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered IV and SC
Drug: Garadacimab
Administered IV and SC
Drug: Placebo
Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
Also known as: Factor XIIa antagonist monoclonal antibody, CSL312
Participants received a matching placebo IV loading dose, followed by 3 SC doses.
Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs)
A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event.
Time frame: Up to 22 weeks
Percentage of Participants With TE SAEs
A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event
Time frame: Up to 22 weeks
Number of Participants With TE Adverse Events of Special Interests (AESIs)
The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.
Time frame: Up to 22 weeks
Percentage of Participants With TE-AESIs
The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.
Time frame: Up to 22 weeks
Number of Participants With Garadacimab Induced Anti Drug Antibodies (ADAs) in Plasma
Time frame: At Day 36 and Day 92 after the first treatment
Percentage of Participants With Garadacimab Induced ADAs in Plasma
Time frame: At Day 36 and Day 92 after the first treatment
Number of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs)
Time frame: Up to 14 weeks after treatment
Percentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEs
Time frame: Up to 14 weeks after treatment
Trough Plasma Concentration (Ctrough) After SC Administration of Garadacimab
Time frame: At Day 36 and Day 64
Maximum Plasma Concentration (Cmax) (Last SC Dosing Interval Only) of Garadacimab
Time frame: After dosing on Day 64
Time to Maximum Plasma Concentration (Tmax) (Last SC Dosing Interval Only) of Garadacimab
Time frame: After dosing on Day 64
Area Under the Plasma Concentration-time Curve Over the Dose Interval (AUC0-tau) (Last SC Dosing Interval Only) of Garadacimab
Time frame: After dosing on Day 64
Ctrough After IV Administration of Garadacimab
Time frame: At Day 8
Cmax After IV Administration of Garadacimab
Time frame: After dosing on Day 1
Tmax After IV Administration of Garadacimab
Time frame: After dosing on Day 1
Mean Change From Baseline in FXIIa-mediated Kallikrein Activity
Time frame: Baseline and at Day 92
Mean Percentage of Baseline in FXIIa-mediated Kallikrein Activity
Percent baseline is calculated by using the formula visit value / baseline value multiplied by 100, percent baseline is reported as percentage in the outcome measure.
Time frame: Baseline and at Day 92
This study was conducted at 47 study sites in 11 countries (Australia, Austria, Belgium, Canada, Denmark, Germany, Italy, Poland, Spain, the United Kingdom \[UK\], and the United States of America \[USA\]). No participants from Italy were enrolled in the study.
| Milestone | Garadacimab | Placebo |
|---|---|---|
| Started | 40 | 41 |
| Completed | 38 | 36 |
| Not completed | 2 | 5 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event.
| Participants | Garadacimab | Placebo |
|---|---|---|
| Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs) | 5 | 2 |
A TE SAE is defined as an SAE reported at or after the start of the first administration of study treatment. A SAE is defined as any untoward medical occurrence that at any dose results in: death, life-threatening event, initial or prolongation of existing hospitalization, disability or incapacity, congenital anomaly or birth defect, or any other medically significant event
| Percentage of participants | Garadacimab | Placebo |
|---|---|---|
| Percentage of Participants With TE SAEs | 12.5 | 4.9 |
The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.
| Participants | Garadacimab | Placebo |
|---|---|---|
| Number of Participants With TE Adverse Events of Special Interests (AESIs) | 2 | 0 |
The following TEAEs were considered as AESIs: Bleeding events that were abnormal in the opinion of the Investigator, Thromboembolic events (non-systemic thrombosis \[e.g., localized thrombosis associated with vascular access\] was not considered an AESI), and Severe hypersensitivity including anaphylaxis.
| Percentage of participants | Garadacimab | Placebo |
|---|---|---|
| Percentage of Participants With TE-AESIs | 5.0 | 0 |
| Participants | Garadacimab | Placebo |
|---|---|---|
| At Day 36 | 1 | 2 |
| At Day 92 | 1 | 1 |
| Percentage of participants | Garadacimab | Placebo |
|---|---|---|
| At Day 36 | 2.6 | 5.4 |
| At Day 92 | 2.6 | 2.8 |
| Participants | Garadacimab | Placebo |
|---|---|---|
| Number of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs) | 0 | 0 |
| Percentage of participants | Garadacimab | Placebo |
|---|---|---|
| Percentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEs | 0.0 | 0.0 |
| Microgram/milliliter (ug/mL) | Garadacimab |
|---|---|
| At Day 36 | 16.445 ± 6.0362 |
| At Day 64 | 17.123 ± 7.9383 |
| ug/mL | Garadacimab |
|---|---|
| Maximum Plasma Concentration (Cmax) (Last SC Dosing Interval Only) of Garadacimab | 37.41 ± 15.507 |
| Hours (h) | Garadacimab |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) (Last SC Dosing Interval Only) of Garadacimab | 165.4585 (45.250 to 478.633) |
| h*ug/mL | Garadacimab |
|---|---|
| Area Under the Plasma Concentration-time Curve Over the Dose Interval (AUC0-tau) (Last SC Dosing Interval Only) of Garadacimab | 18094.6128 ± 6977.9036 |
| ug/mL | Garadacimab |
|---|---|
| Ctrough After IV Administration of Garadacimab | 18.6054 ± 7.9685 |
| ug/mL | Garadacimab |
|---|---|
| Cmax After IV Administration of Garadacimab | 79.636 ± 31.4406 |
| h | Garadacimab |
|---|---|
| Tmax After IV Administration of Garadacimab | 0.1000 (0.017 to 0.967) |
| Nanomoles/liter/minutes (nmol/L/mins) | Garadacimab | Placebo |
|---|---|---|
| Mean Change From Baseline in FXIIa-mediated Kallikrein Activity | -0.0258 ± 0.0657 | 0.0072 ± 0.0706 |
Percent baseline is calculated by using the formula visit value / baseline value multiplied by 100, percent baseline is reported as percentage in the outcome measure.
| Percent baseline | Garadacimab | Placebo |
|---|---|---|
| Mean Percentage of Baseline in FXIIa-mediated Kallikrein Activity | 129.56 ± 215.689 | 124.83 ± 68.872 |
Collected over Up to 22 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Garadacimab | 1/40 (2.5%) | 5/40 (12.5%) | 18/40 (45%) |
| Placebo | 1/41 (2.4%) | 2/41 (4.9%) | 19/41 (46.3%) |
| Event | Garadacimab | Placebo |
|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 3/40 | 0/41 |
| Pancreatitis acuteGastrointestinal disorders | 1/40 | 0/41 |
| PneumoniaInfections and infestations | 1/40 | 0/41 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/40 | 1/41 |
| Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders | 0/40 | 1/41 |
| COVID-19Infections and infestations | 0/40 | 1/41 |
| Event | Garadacimab | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/40 | 5/41 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/40 | 5/41 |
| DizzinessNervous system disorders | 2/40 | 4/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/40 | 4/41 |
| FatigueGeneral disorders | 3/40 | 3/41 |
| BronchitisInfections and infestations | 3/40 | 2/41 |
| Urinary tract infectionInfections and infestations | 3/40 | 1/41 |
| C-reactive protein increasedInvestigations | 1/40 | 3/41 |
| Abdominal discomfortGastrointestinal disorders | 2/40 | 0/41 |
| Non-cardiac chest painGeneral disorders | 2/40 | 1/41 |
| Age, Categorical(Participants) | Garadacimab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 5 |
| >=65 years | 38 | 38 | 76 |
| Age, Continuous(years) | Garadacimab | Placebo | Total |
|---|---|---|---|
| Mean | 72.6 ± 6.19 | 72.9 ± 6.17 | 72.8 ± 6.14 |
| Sex: Female, Male(Participants) | Garadacimab | Placebo | Total |
|---|---|---|---|
| Female | 14 | 21 | 35 |
| Male | 26 | 20 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Garadacimab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 37 | 39 | 76 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Garadacimab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 40 | 40 | 80 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Garadacimab | Placebo | Total |
|---|---|---|---|
| Canada | 1 | 0 | 1 |
| Austria | 3 | 0 | 3 |
| Belgium | 0 | 3 | 3 |
| United States | 19 | 21 | 40 |
| Poland | 5 | 4 | 9 |
| Denmark | 3 | 2 | 5 |
| United Kingdom | 4 | 4 | 8 |
| Australia | 1 | 0 | 1 |
| Germany | 3 | 4 | 7 |
| Spain | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
Ran from Feb 2022 to primary completion in Jan 2024, 22 months.
Results were first posted in Dec 2024, 11 months after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 22 months is below that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garadacimab
Idiopathic Pulmonary Fibrosis →